Keen M L
ANNA J. 1990 Aug;17(4):318-9.
Epoetin alfa (EPOGEN, recombinant human erythropoietin) has proven to be a major therapeutic advance in treating the chronic refractory anemia associated with end-stage renal disease (ESRD). As with many medications, the dose of Epoetin alfa must be individualized for each patient. In order to elicit a consistent production of red cells from the bone marrow, it is desirable that dose modifications be made as infrequently as possible. Gotch and Uehlinger have developed a kinetic model that can limit dose modifications by predicting the optimal dose of Epoetin alfa for each patient. Termed the Erythrokinetic Model, it compares individual patient response to Epoetin alfa to the life cycle of a red blood cell. This article describes the Gotch/Uehlinger Erythrokinetic Model and uses it to gauge the clinical response of 2 patients to Epoetin alfa.
促红细胞生成素α（益比奥，重组人促红细胞生成素）已被证明是治疗终末期肾病（ESRD）相关慢性难治性贫血的一项重大治疗进展。与许多药物一样，促红细胞生成素α的剂量必须针对每个患者进行个体化调整。为了促使骨髓持续产生红细胞，希望尽可能少地进行剂量调整。戈奇和于林格开发了一种动力学模型，该模型可以通过预测每个患者的促红细胞生成素α最佳剂量来限制剂量调整。该模型称为红细胞动力学模型，它将个体患者对促红细胞生成素α的反应与红细胞的生命周期进行比较。本文介绍了戈奇/于林格红细胞动力学模型，并使用该模型评估了2例患者对促红细胞生成素α的临床反应。
